MANA-412 / MANA Therap - LARVOL DELTA

MANA Therapeutics Announces Final Closing of Series A and Closing of Venture Debt Facility (Businesswire) - "Financing to be used to advance MANA-312 and MANA-412...This is encouraging progress and the data we are collecting will inform the development of our off-the-shelf programs, including MANA-412, which is expected to advance into clinical trials in 2022..."

Commercial • New trial • Oncology

MANA Therapeutics Launches with $35 Million Series A Financing (Businesswire) - "Financing to support the MANA-312 Phase 1 study, now underway in patients with AML/MDS after allogeneic HSCT, and accelerate preclinical development of off-the-shelf allogeneic programs...'MANA-412, for which we plan to file an IND in late-2021.'"

Financing • IND • Trial status • Acute Myelogenous Leukemia • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • Solid Tumor